Leader of Tomorrow’s Novartis BioCamp Experience

Adam was a Leader of Tomorrow at GapSummit 2016 and has continued to Grow, Connect and Challenge through global events. He shared with us his recent experience attending the Novartis International Biotechnology Leadership Camp (BioCamp), a 3-day event that gives 60 select students an in-depth look inside the company. I am always looking for ways in which I can acquire more knowledge on the inner workings of the biotech industry being an aspiring biotech leader myself. After I arrived in the UK for my Masters, I was lucky to be chosen to attend…Read more

Brexit: What it means for UK Biotech?

Global Biotech Revolution stands for the values of connecting and growing the global bio-economy through inter-generational debate. The referendum result in favour of the UK leaving the EU has caused major discontent from the younger voting demographic, most of whom voted to "Remain". This vote affects young researchers and world-class UK universities who receive a significant contribution through EU scholarships, research funding and most importantly collaborations. It affects enterprising young people who would seek to engage the UK's entrepreneurial ecosystems to build businesses and create jobs and growth. These are tumultuous times for…Read more

Q&A: Harriet Fear, CEO, One Nucleus

Harriet Fear, MBE is CEO of One Nucleus, the largest international membership organisation for life science and healthcare companies in Europe, based in Cambridge, UK. We had a chance to get some insights from Harriet ahead of the upcoming ON Helix Conference. Cambridge is regarded as one of the most successful entrepreneurial ecosystems in the world, and a hub of life sciences activity. What do you think are the key factors that have contributed to this success? Harriet: It is! I think there are many contributing factors to any sort of success, and…Read more

Global Biotech Revolution C.I.C. announces our partnership with One Nucleus

Global Biotech Revolution C.I.C. (GBR) is pleased to announce our partnership with One Nucleus to co-promote each organisation’s upcoming events for the benefit of the UK’s biotechnology sector. One Nucleus is a membership organisation for international life science and healthcare companies. Based in Cambridge and London UK, the heart of Europe’s largest life science and healthcare cluster; One Nucleus’s mission is to maximise the global competitiveness of their members. “We are very happy to partner with a leading industry organisation such as One Nucleus” said Ipshita Mandal, President of GBR. “We want to provide young bio-leaders…Read more

Synthetic Biology Continues to Grow in the U.S., Raising More than $0.5B in 2015

In the past year, industrial applications for synthetic biology have simply exploded. Just in 2015, SynBio companies in the United States have raised more than half a billion dollars to advance fields as diverse as personalized medicine and next-generation textiles. The dramatic increase in synbio investment is primarily concentrated in two transcostal hubs: the greater San Francisco and Boston areas. Companies in San Francisco have benefitted from a very supportive startup culture, taking advantage of infrastructure laid down from years of Silicon Valley endeavours. The startup process has been streamlined in the area…Read more

What are the key factors to let Synthetic Biotechnology flourish in the UK?

The excitement in the synthetic biology community in the UK is palpable. It’s apparent in the buzz at SynBio meetings and conferences, but also evident by the sector’s rapid growth in the UK in the last five years. Thanks to the UK government’s pro-active mindset towards the industry - having identified SynBio as one of its seven key enabling technologies, it is perhaps the only country to have a coordinated and cohesive SynBio plan in place (in the form of the Synthetic Biology Roadmap). SynBio companies that set up shop in the UK…Read more

The implementation gap

The implementation gap In 2012, the biotech industries of the US, Europe, Canada and Australia realized an 8% increase in revenue from 2011 with US$89.8 billion. At the same time, the R&D spending growth rate of 9% in 2011 was slowed down to 5% a year later, which still resulted in a record high in net income of US$5.2 billion. However, the total funding has decreased in North America and Europe to US$28.2 billion in 2012. Hence, one can expect strong performances from major biotech players, whereas small- to mid-size companies stand in…Read more